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Histiocytes and dendritic cells belong to a group of immuno-
regulatorycellsthatareresponsibleforantigenprocessingand
presentation to lymphocytes. Neoplasms of histiocytic and
dendritic origin are very rare [1], making up less than 1% of
tumours in lymph nodes. Thus, information regarding
epidemiology, prognosis and treatment [2, 3]i ss c a r c e .
Table 1 summatizes the neoplasms derived from histiocytes
and other accessory cells according to the 2001 and 2008
WHO classification.
A new entity that has been added to the 2008 WHO
classification of histiocytic dendritic cell neoplasms is
disseminated juvenile xanthogranuloma (JXG). JXG is a
benign proliferation of histiocytes similar to those that
occur in the dermis. The disease that occurs in adults with
bone and lung involvement is referred to as Erdheim–
Chester disease. Although most JXG are benign, activation
of macrophages can lead to cytopenias, liver damage and
death. Neoplastic cells are composed of small and oval to
spindled histiocytes with bland nuclear features without
nuclear grooves. Dermal lesions tend to have foamy
(xanthomatous) cytoplasm with Touton-type giant cells.
Similar to macrophages, the tumour cells express CD14,
CD68 and fascin. CD1a is negative and S100 is positive in
less than 20% of the cases. Some are clonal but no
cytogenetic or molecular changes have been identified. An
association with neurofibromatosis type 1 has been made.
Although the neoplastic cells are thought to be derived
from dendritic cells, they were previously classified as soft
tissue tumours. The recognition of their origin from
dermal/interstitial dendritic cells and association with other
hematologic malignancies such as juvenile myelomono-
cytic leukaemia and Langerhans cell disease warranted
their classification within the category of histiocytic
and dendritic cell neoplasms. It is unclear whether the
solitary forms of JXG should be considered a benign
counterpart of disseminated JXG. In addition, the range of
cytologic atypia that is exhibited by these tumours is also
unknown.
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Table 1 A summary of the neoplasms derived from histiocytes and
other accessory cells in the 2001 and 2008 WHO classification
2001 WHO
classification
2008 WHO
classification
Comments
Histiocytic
sarcoma
Histiocytic sarcoma No change
Langerhans cell
histiocytosis
Langerhans cell
sarcoma
Tumours derived from
Langerhans cells
(Langerhans cell
histiocytosis,
Langerhans cell
sarcoma)
No change
Interdigitating
dendritic cell
sarcoma/tumour
Interdigitating
dendritic cell
sarcoma
Use sarcoma
terminology
Follicular
dendritic cell
sarcoma/tumour
Follicular dendritic
cell sarcoma
Use sarcoma
terminology
Dendritic cell
sarcoma, NOS
Other rare dendritic
cell tumours
including
indeterminate
dendritic cell tumour,
fibroblastic reticular
Addition of 2 other
tumours of dendritic
origin to recognise
myeloid and stroma-
deriveddendriticcells
Disseminated juvenile
xanthogranuloma
New entity
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e-mail: meganlim@umich.eduIn the 2008 WHO classification, interdigitating dendritic
cell sarcoma/tumours are to be designated interdigitating
dendritic cell sarcoma, and follicular dendritic cell sarcoma/
tumours are to be designated follicular dendritic cell sarcomas
to better reflect their malignant potential.
In contrast to the 2001 WHO classification, the 2008
WHO classification recognises two additional subtypes of
rare dendritic cell tumours. These are encompassed by the
term “other rare dendritic cell tumours” and include those
that are myeloid-derived dendritic cells such as indetermi-
nate dendritic cell tumour and those that are derived from
stroma-derived dendritic cells such as fibroblastic reticular
cell tumour. These replace the generic category of dendritic
cell sarcoma, not otherwise specified. In addition, those that
remain unclassifiable despite extensive workup or show
hybrid features should be designated “dendritic cell
tumour”, not otherwise specified.
What remains unclear is the absence of criteria or
terminology to recognise the spectrum of malignant
potential for follicular dendritic cell sarcomas and interdig-
itating dendritic cell sarcomas.
In summary, this group of neoplasms remains a diagnostic
and clinical challenge. Due to the lack of phenotypic markers
that are unique for most of the subtypes of tumours in this
category, extensive panel of immunohistochemical stains in
addition to molecular analyses are required. Furthermore,
there are no useful stains or molecular studies to distinguish
the neoplasms from reactive counterparts.
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